NCCN Guidelines® insights: Non-Hodgkin's lymphomas, version 3.2016: Featured updates to the NCCN guidelines Journal Article


Authors: Horwitz, S. M.; Zelenetz, A. D.; Gordon, L. I.; Wierda, W. G.; Abramson, J. S.; Advani, R. H.; Andreadis, C. B.; Bartlett, N.; Byrd, J. C.; Fayad, L. E.; Fisher, R. I.; Glenn, M. J.; Habermann, T. M.; Harris, N. L.; Hernandez-Ilizaliturri, F.; Hoppe, R. T.; Kaminski, M. S.; Kelsey, C. R.; Kim, Y. H.; Krivacic, S.; La Casce, A. S.; Lunning, M.; Nademanee, A.; Press, O.; Rabinovitch, R.; Reddy, N.; Reid, E.; Roberts, K.; Saad, A. A.; Sokol, L.; Swinnen, L. J.; Vose, J. M.; Yahalom, J.; Zafar, N.; Dwyer, M.; Sundar, H.; Porcu, P.
Article Title: NCCN Guidelines® insights: Non-Hodgkin's lymphomas, version 3.2016: Featured updates to the NCCN guidelines
Abstract: Peripheral T-cell lymphomas (PTCLs) represent a relatively uncommon heterogeneous group of non-Hodgkin's lymphomas (NHLs) with an aggressive clinical course and poor prognosis. Anthracycline-based multiagent chemotherapy with or without radiation therapy followed by first-line consolidation with high-dose therapy followed by autologous stem cell rescue (HDT/ASCR) is the standard approach to most of the patients with newly diagnosed PTCL. Relapsed or refractory disease is managed with second-line systemic therapy followed by HDT/ASCR or allogeneic stem cell transplant, based on the patient's eligibility for transplant. In recent years, several newer agents have shown significant activity in patients with relapsed or refractory disease across all 4 subtypes of PTCL. These NCCN Guideline Insights highlight the important updates to the NCCN Guidelines for NHL, specific to the management of patients with relapsed or refractory PTCL. © JNCCN-Journal of the National Comprehensive Cancer Network.
Journal Title: Journal of the National Comprehensive Cancer Network
Volume: 14
Issue: 9
ISSN: 1540-1405
Publisher: Harborside Press  
Date Published: 2016-09-01
Start Page: 1067
End Page: 1079
Language: English
PROVIDER: scopus
PUBMED: 27587620
DOI: 10.6004/jnccn.2016.0117
DOI/URL:
Notes: Review -- Export Date: 3 October 2016 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Joachim Yahalom
    625 Yahalom
  2. Steven M Horwitz
    645 Horwitz
  3. Andrew D Zelenetz
    767 Zelenetz